Takeda Pharmaceutical Company Limited (NYSE:TAK – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $15.22 and last traded at $15.20, with a volume of 561724 shares. The stock had previously closed at $15.01.
Takeda Pharmaceutical Trading Up 1.1 %
The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The stock has a 50 day simple moving average of $13.76 and a 200-day simple moving average of $13.90. The firm has a market cap of $48.29 billion, a P/E ratio of 37.96, a P/E/G ratio of 0.24 and a beta of 0.46.
Takeda Pharmaceutical (NYSE:TAK – Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, equities research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.
Hedge Funds Weigh In On Takeda Pharmaceutical
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Read More
- Five stocks we like better than Takeda Pharmaceutical
- What is a Secondary Public Offering? What Investors Need to Know
- Can TikTok Stock Picks Really Make You Rich?
- How to Invest in Insurance Companies: A GuideĀ
- The “Quality” Rotation: Back to Basics Investing
- 10 Best Airline Stocks to Buy
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.